Roswell Park Approved to Administer CAR T-Cell Therapy, Yescarta, to Lymphoma Patients – Newswise (press release)
|
Roswell Park Approved to Administer CAR T-Cell Therapy, Yescarta, to Lymphoma Patients
Newswise (press release) Newswise — BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center has been officially approved to administer an FDA-approved CAR T-cell therapy, Yescarta, to lymphoma patients. It's manufactured by Kite, a Gilead Company. Yescarta, also known as … |
